Omalizumab improves asthma-related quality of life in patients with severe allergic asthma
- 1 February 2003
- journal article
- clinical trial
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 111 (2) , 278-284
- https://doi.org/10.1067/mai.2003.54
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- OmalizumabDrugs, 2001
- Treatment of Allergic Asthma with Monoclonal Anti-IgE AntibodyNew England Journal of Medicine, 1999
- Allergic inflammation in upper and lower airwaysAnnals of Allergy, Asthma & Immunology, 1999
- IMMUNOLOGIC BASIS OF ANTIGEN-INDUCED AIRWAY HYPERRESPONSIVENESSAnnual Review of Immunology, 1999
- IgE Inhibition as a Therapy for Allergic DiseaseInternational Archives of Allergy and Immunology, 1999
- Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody.The Journal of Experimental Medicine, 1996
- Sorting out the cytokines of asthma.The Journal of Experimental Medicine, 1996
- Anti-lgE Monoclonal Antibodies that Inhibit Allergen-Specific Histamine ReleaseInternational Archives of Allergy and Immunology, 1995
- Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.Thorax, 1992